CFO Peter Mariani Buys 100,000 Shares of Cytosorbents
Cytosorbents CFO Peter Mariani acquired 100,000 shares worth $44,000 on June 15.
Key Points
- On June 15, 2026, CFO Peter Mariani bought 100,000 shares of Cytosorbents at $0.44 each, totaling $44,000.
- Shares of Cytosorbents (NasdaqCM: CTSO) traded around $0.43, with a market cap of $27.1 million.
- Analysts have set a mean target price of $2.88 for Cytosorbents, with a high of $5.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Cytosorbents Corporation's Chief Financial Officer, Peter Mariani, made a significant purchase of the company's stock on June 15, 2026. Mariani acquired 100,000 shares at an average price of $0.44, resulting in a total transaction value of $44,000. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Cytosorbents Corporation
On the same day, CEO Dr. Phillip Chan also purchased shares, acquiring 10,333 shares at $0.43 each. Earlier, on June 12, Chan bought another 251,136 shares at $0.40. These insider transactions suggest confidence in the company's prospects.
Cytosorbents Corporation Stock Up 28.7%
Shares of Cytosorbents, trading on the NasdaqCM under the ticker CTSO, recently hovered around $0.43. The company has a market capitalization of approximately $27.1 million. Its stock has seen a 52-week low of $0.37 and a high of $1.39. The 50-day moving average stands at $0.55, while the 200-day moving average is $0.71. The company's financial ratios include a current ratio of 1.089, a quick ratio of 0.734, and a high debt-to-equity ratio of 1334.366.
Analysts Set New Price Targets
Analysts have been maintaining their positions on Cytosorbents. On January 12, 2026, D. Boral Capital maintained a 'buy' rating with a price target of $10.00. The general analyst consensus sets a mean target price of $2.88, based on two opinions.
About Cytosorbents Corporation
Cytosorbents Corporation, headquartered in Princeton, New Jersey, is a healthcare company specializing in medical devices. It focuses on blood purification technologies, with its flagship product, CytoSorb, used to treat cytokine storms in critical illnesses. The company operates in the United States, Germany, and internationally, and is led by CEO Dr. Phillip P. Chan.
Bottom Line
The recent insider purchases by CFO Peter Mariani and CEO Dr. Phillip Chan highlight their confidence in Cytosorbents' future. Investors often watch such transactions for insights into company sentiment. While the stock's recent performance has been mixed, analysts maintain a positive outlook with a high target price. However, it's important to remember that insider transactions are just one of many factors investors consider.
Get Cytosorbents Corporation alerts
New 13F filings, insider trades, and analyst moves on $CTSO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.